Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC
Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC is organized by Physicians' Education Resource, LLC (PER).
Release Date: January 31, 2023
Expiration Date: January 31, 2024
Description:
This Burst CME: Mapping Out the Role of Emerging Biomarkers and Testing in NSCLC is an interview-based program in which an expert discusses the importance of genetic testing in patients with non–small cell lung cancer (NSCLC). It is recommended that patients with NSCLC are tested for actionable biomarkers prior to immunotherapy treatment to ensure the best response. This will be presented in a multimedia format, including audio interviews integrated into text-based elements.
Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Describe testing methods and relevant targets that may be used to inform clinical decisions in patients with NSCLC and fusions of ROS1 or NTRK
• Interpret current efficacy and safety data from trials that leveraged precision testing strategies among patients with advanced NSCLC
• Explain emerging therapies that target ROS1 and NTRK in development to manage patients with advanced NSCLC.